Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.
Keywords: bleomycin; infliximab; intensive care; pulmonary toxicity; respiratory failure; treatment outcome.